4/19/2021
by CARRIE N. BAKER
Last Monday, the U.S. Food and Drug Administration (FDA) issued long-awaited guidance lifting a restriction on the abortion pill mifepristone for the duration of the COVID-19 public health emergency. The move permits telemedicine abortion, a combination of medication abortion—using pills to end a pregnancy—and telemedicine, which allows health providers to supervise the use of abortion pills via videoconferencing or telephone consultations.
Dr. Janet Woodcock, the acting FDA commissioner, wrote in a letter to the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine that the FDA will waive a requirement that clinicians dispense the abortion pill mifepristone to their patients in a clinic or hospital setting. The letter said research studies on telemedicine abortion “do not appear to show increases in serious safety concerns occurring with medical abortion as a result of modifying the in-person dispensing requirement during the COVID-19 pandemic.”
Continued: https://msmagazine.com/2021/04/19/fda-telemedicine-abortion-pill-mifepristone/